UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

The American journal of psychiatry, 2008-08, Vol.165 (8), p.1033-1039

2008

Volltextzugriff (PDF)

The Discovery of Fluoxetine Hydrochloride (Prozac)

Nature reviews. Drug discovery, 2005-09, Vol.4 (9), p.764-774

2005

Volltextzugriff (PDF)

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

Pharmacological reviews, 2008-09, Vol.60 (3), p.358-403

2008

Volltextzugriff (PDF)

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Neuropharmacology, 2006-05, Vol.50 (6), p.755-760

2006

Volltextzugriff (PDF)

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

Synapse (New York, N.Y.), 2012-06, Vol.66 (6), p.522-532

2012

Volltextzugriff (PDF)

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

Psychopharmacology, 2013-03, Vol.226 (2), p.189-200

2013

Volltextzugriff (PDF)

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

The Journal of pharmacology and experimental therapeutics, 2002-06, Vol.301 (3), p.1020-1024

2002

Volltextzugriff (PDF)

A Novel Augmentation Strategy for Treating Resistant Major Depression

The American journal of psychiatry, 2001-01, Vol.158 (1), p.131-134

2001

Volltextzugriff (PDF)

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

British journal of pharmacology, 2003-02, Vol.138 (4), p.544-553

2003

Volltextzugriff (PDF)

Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates

PloS one, 2015-04, Vol.10 (4), p.e0122722-e0122722

2015

Volltextzugriff (PDF)

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Journal of medicinal chemistry, 2000-11, Vol.43 (23), p.4333-4353

2000

Volltextzugriff (PDF)

Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system

Neurochemical research, 2003-04, Vol.28 (3-4), p.437-442

2003

Volltextzugriff (PDF)

Muscarinic mechanisms in psychotic disorders

Handbook of experimental pharmacology, 2012 (213), p.233

2012

Volltextzugriff (PDF)

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity

The European journal of neuroscience, 2003-04, Vol.17 (7), p.1403-1410

2003

Volltextzugriff (PDF)

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity

Synapse (New York, N.Y.), 2012-05, Vol.66 (5), p.435-444

2012

Volltextzugriff (PDF)

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat

Neuropharmacology, 2004-02, Vol.46 (2), p.232-242

2004

Volltextzugriff (PDF)

Case history: the discovery of fluoxetine hydrochloride (Prozac)

Nature reviews. Drug discovery, 2005-09, Vol.4 (9), p.764-774

2005

Volltextzugriff (PDF)

Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder

Journal of experimental pharmacology, 2024, Vol.16, p.13-24

2024

Volltextzugriff (PDF)

Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

European journal of pharmacology, 2001-11, Vol.430 (2-3), p.341-349

2001

Volltextzugriff (PDF)

Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease

Proceedings of the National Academy of Sciences - PNAS, 2001-12, Vol.98 (25), p.14669-14674

2001

Volltextzugriff (PDF)

Biopharmaceutical Characterization, Metabolism, and Brain Penetration of the Triple Reuptake Inhibitor Amitifadine

Drug metabolism letters, 2013-03, Vol.7 (1), p.23-33

2013

Volltextzugriff (PDF)

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

Current pharmaceutical design, 2005-05, Vol.11 (12), p.1475-1493

2005

Volltextzugriff (PDF)

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Psychopharmacologia, 2002-04, Vol.160 (4), p.353-361

2002

Volltextzugriff (PDF)

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody

The Journal of clinical investigation, 2006-03, Vol.116 (3), p.825-832

2006

Volltextzugriff (PDF)

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats

European journal of pharmacology, 2015-10, Vol.764, p.30-37

2015

Volltextzugriff (PDF)

1 – 25 von 140

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieNeuropsychopharmacology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(116)

Publikationsform

Artikel
(139)
Buchkapitel
(1)

Sprache

Englisch
(140)
Japanisch
(31)

Erscheinungsjahr

n.n

Thema

Science & Technology
(82)
Life Sciences & Biomedicine
(78)
Animals
(77)
Pharmacology & Pharmacy
(53)
Male
(47)
Biological And Medical Sciences
(42)
Rats
(41)
Humans
(38)
Medical Sciences
(35)
Pharmacology. Drug Treatments
(31)
Neuropharmacology
(29)
Mice
(28)
Muscarinic Agonists - Pharmacology
(22)
Neurosciences & Neurology
(22)
Neurosciences
(21)
Dose-Response Relationship, Drug
(20)
Psychology. Psychoanalysis. Psychiatry
(18)
Psychopharmacology
(18)
Microdialysis
(16)
Receptors, Muscarinic - Drug Effects
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

The Discovery of Fluoxetine Hydrochloride (Prozac)

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

A Novel Augmentation Strategy for Treating Resistant Major Depression

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system

Muscarinic mechanisms in psychotic disorders

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat

Case history: the discovery of fluoxetine hydrochloride (Prozac)

Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder

Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease

Biopharmaceutical Characterization, Metabolism, and Brain Penetration of the Triple Reuptake Inhibitor Amitifadine

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats

Aktive Filter

Suchergebnisse filtern